Pfizers Xeljanz In the Crowded Rheumatoid Drugs Market – Forbes

Pfizer Inc. signage is displayed on a monitor on the floor of the New York Stock Exchange (NYSE) in ... [+] New York, U.S., on Friday, April 22, 2016. The Standard & Poor's 500 Index was little changed after retreating from a four-month high, as gains in oil lifted commodity producers to help offset weaker-than-forecast earnings from Microsoft Corp. and Google parent Alphabet Inc. Photographer: Michael Nagle/Bloomberg

Pfizers(NYSE: PFE) Rheumatoid Arthritis drug ~ Xeljanz ~ is a relatively small drug with sales of around $2 billion, and it accounts for around 4% of the total rheumatoid arthritis drugs market. AbbVies Humira is the leader based on drugs total sales. However, Humira is used for other indications as well, such as Crohns Disease and Ulcerative colitis among others. Rheumatoid arthritis refers to a long term autoimmune disorder related to joints. Pfizers Xeljanz is protected from any biosimilar competition till 2025, and it could see sales growth in the near term. The drug has demonstrated to be non-inferior to Humira for patients with moderate to severe rheumatoid arthritis. However, sales growth will likely be slower going forward, amid tough competition from other pharmaceutical companies in the crowded rheumatoid arthritis drugs market.

The market (ten drugs listed in the dashboard) is expected to see a decline in sales going forward, as J&Js Remicade is facing biosimilar competition after its patent loss in 2016, and it already lost $1.6 billion in sales between 2016-2018. It will likely lose another $2.6 billion by 2021, in our view, thus offsetting the growth from other drugs. The new biosimilars for Remicade are not added in the list of drugs below. Note that most of the drugs mentioned below are approved for multiple disorders, and the sales figures represent the total revenue in the immunology area. Look at our interactive dashboard analysis ~ How Is Pfizers Xeljanz Placed In Rheumatoid Arthritis Drugs Market? ~ for more details.

AbbVies Humira Is The Top Selling Rheumatoid Arthritis Drug, Followed By Johnson & Johnsons Remicade And Amgens Enbrel

Combined Sales of Rheumatoid Arthritis Drugs Above Grew From $33.8 Billion In 2014 To $43.0 Billion In 2018. Xeljanzs Share Increased From 1% To 4% During The Same Period, And It Could Grow To 6% Over The Next Few Years.

Trefis

Xeljanzs Market Exclusivity Period Ends In 2025 While The Leader Humiras Ends In 2023. As Shown Below

Xeljanz Is a Relatively Small Drug For Pfizer, And It Accounts For Only 4% of The Companys Total Sales

Whats behind Trefis? See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams|Product, R&D, and Marketing Teams More Trefis Data Like our charts? Exploreexample interactive dashboardsand create your own

Continue reading here:
Pfizers Xeljanz In the Crowded Rheumatoid Drugs Market - Forbes